The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Open accessAbstract
Background In vitro, disulfiram activated HIV transcription in a primary T-cell model of HIV latency and in a pilot clinical study increased plasma HIV RNA in individuals with adequate drug exposure. We assessed the effect of disulfiram on HIV transcription in a dose-escalation study.Methods In this prospective dose-escalation study, to optimise disulfiram exposure we included adults with HIV on suppressive antiretroviral therapy, with plasma HIV RNA of less than 50 copies per mL and a CD4 cell count greater than 350 cells per μL. Participants were allocated sequentially to one of three dosing groups (500 mg, 1000 mg, and 2000 mg) and received disulfiram daily for 3 days. Only the staff who did laboratory assays were masked to group assignment. The primary endpoint was change in cell-associated unspliced HIV RNA in CD4 cells. The primary analysis method was a negative binomial regression, with the number of copies as the outcome variable and the input total RNA or plasma volume as an exposure variable, which is equivalent to modelling copies or input. We used these models to estimate changes from before disulfiram to timepoints during and after disulfiram administration. This study is registered with ClinicalTrials.gov, number NCT01944371.Findings Of 34 participants screened for eligibility at The Alfred Hospital (Melbourne, VIC, Australia), and San Francisco General Hospital (San Francisco, CA, USA), 30 people were enrolled between Sept 24, 2013, and March 31, 2014. The estimated fold increases in cell-associated unspliced HIV RNA from baseline were 1·7 (95% CI 1·3-2·2; p<0·0001) to the timepoint during disulfiram treatment and 2·1 (1·5-2·9; p<0·0001) to the timepoint after disulfiram in the 500 mg group; 1·9 (1·6-2·4; p<0·0001) and 2·5 (1·9-3·3; p<0·0001) in the 1000 mg group; and 1·6 (1·2-2·1; p=0·0026) and 2·1 (1·5-3·1; p=0·0001) in the 2000 mg group. No deaths occurred, and no serious adverse events were noted. Disulfiram was well tolerated at all doses.Interpretation Short-term administration of disulfiram resulted in increases in cell-associated unspliced HIV RNA at all doses, consistent with activating HIV latency. Disulfiram may be suited for future studies of combination and prolonged therapy to activate latent HIV.Funding The Foundation for AIDS Research (amfAR); National Institute of Allergy and Infectious Diseases, National Institutes of Health; Australian National Health and Medical Research Council.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, a short-term dose-escalation study (NCT01944371) confirmed DIS’s safety and tolerability, showing elevated plasma HIV RNA at higher doses.32”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“DIS reactivates HIV transcription in latently infected cell lines by depleting phosphatase and tensin homolog (PTEN), which activates protein kinase B (PKB/Akt) signaling and boosts downstream HIV gene expression.32,92”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Decay characteristics of HIV-1-infected compartments during combination therapy
Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., & Ho, D. D. (1997) · Nature · doi:10.1038/387188a0 · Cited by 1,880
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 Replication
König, R., Zhou, Y., Elleder, D., Diamond, T. L., Bonamy, G. M. C., Irelan, J. T., Chiang, C.-Y., Tu, B. P., De Jesus, P. D., Lilley, C. E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.032 · Cited by 960
Circadian Regulator CLOCK Is a Histone Acetyltransferase
Doi, M., Hirayama, J., & Sassone-Corsi, P. (2006) · Cell · doi:10.1016/j.cell.2006.03.033 · Cited by 887
HIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
Self-citationRasmussen, T. A., Tolstrup, M., Brinkmann, C. R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al. (2014) · The Lancet HIV · doi:10.1016/s2352-3018(14)70014-1 · Cited by 628
Self-citationDeeks, S. G. (2012) · Nature · doi:10.1038/487439a · Cited by 604
Self-citationVan Lint, C., Emiliani, S., Ott, M., & Verdin, E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00449.x · Cited by 580
Research works printed but not linked: 1
- Williams, 1937, Effects of alcohol on workers with carbon disulfide, J Am Med Assoc, 109, 1472
Cited by
The hallmarks of COVID-19 disease
Tang, D., Comish, P., & Kang, R. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008536 · Cited by 447
International AIDS Society global scientific strategy: towards an HIV cure 2016
International AIDS Society Towards a Cure Working Group, Deeks, S. G., Lewin, S. R., Ross, A. L., Ananworanich, J., Benkirane, M., Cannon, P., Chomont, N., Douek, D., Lifson, J. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4108 · Cited by 425
Self-citationCD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
Fromentin, R., Bakeman, W., Lawani, M. B., Khoury, G., Hartogensis, W., DaFonseca, S., Killian, M., Epling, L., Hoh, R., Sinclair, E., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005761 · Cited by 422
Self-citationGetting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV
Kim, Y., Anderson, J. L., & Lewin, S. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.004 · Cited by 414
Self-citationResearch priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Deeks, S. G., Archin, N., Cannon, P., Collins, S., Jones, R. B., de Jong, M. A. W. P., Lambotte, O., Lamplough, R., Ndung’u, T., Sugarman, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01590-5 · Cited by 377
Self-citation
Metadata
- Authors
- Elliott, J. H., McMahon, J. H., Chang, C. C., Lee, S. A., Hartogensis, W., Bumpus, N., Savic, R., Roney, J., Hoh, R., Solomon, A., Piatak, M., Gorelick, R. J., Lifson, J., Bacchetti, P., Deeks, S. G., & Lewin, S. R.
- Affiliations
- The Alfred Hospital (AU)
- The University of Melbourne (AU)
- University of California, San Francisco (US)
- Leidos Biomedical Research Inc. (United States) (US)
- Corresponding author
- Lewin, Sharon R
- ORCID
- Venue
- The Lancet HIV
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 2
- Issue
- 12
- Pages
- e520-e529
- ISSN
- 2352-3018 (ISSN-L)
- PMC
- PMC5108570
- OpenAlex
- W2177904182
- Cited by
- 250
- References
- 29
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 9 · 2023: 24 · 2022: 22 · 2021: 25 · 2020: 32 · 2019: 25 · 2018: 43 · 2017: 25 · 2016: 14 · 2015: 4
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet HIV (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Foundation for AIDS Research (amfAR; 108465-52-RGRL)
- Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health (U19AI096109)
- NIAID (K24 AI069994)
- UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- disulfiram, HIV latency, HIV transcription, CD4+ T cells, dose escalation, antiretroviral therapy, HIV reservoir, HIV cure, negative binomial regression, adverse events, tolerability
- MeSH terms
- Adult, Australia, Disulfiram, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, RNA, Viral, Transcription, Genetic, United States, CD4-Positive T-Lymphocytes, HIV-1, HIV Infections, Treatment Outcome, Virus Latency, CD4 Lymphocyte Count, Viral Load, Anti-Retroviral Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. https://app.cochat.ai/papers/10.1016/s2352-3018(15)00226-x
- The paper
- Elliott, J. H., McMahon, J. H., Chang, C. C., Lee, S. A., Hartogensis, W., Bumpus, N., Savic, R., Roney, J., Hoh, R., Solomon, A., Piatak, M., Gorelick, R. J., Lifson, J., Bacchetti, P., Deeks, S. G., & Lewin, S. R. (2015). Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. The Lancet HIV. https://doi.org/10.1016/s2352-3018(15)00226-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.